Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.4043
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 211202733300.0
- FreeCF/Share 6.7321
- PFCF 12.3953
- PE 12.2108
- Debt/Assets 0.3027
- DivYield 0.038
- ROE 0.3816
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Published: June 27, 2025 by: Seeking Alpha
Sentiment: Positive
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting the urgent need for diversification.
Read More
ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.
Read More
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Read More
RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
Published: June 26, 2025 by: CNBC
Sentiment: Positive
Health and Human Services Secretary Robert F. Kennedy Jr.'s revamped government panel of vaccine advisors recommended the use of Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus.
Read More
US CDC panel votes in favor of Merck's RSV antibody drug
Published: June 26, 2025 by: Reuters
Sentiment: Positive
An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, whose mother did not receive a preventive shot during pregnancy.
Read More
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
Read More
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Read More
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clin.
Read More
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
Published: June 18, 2025 by: CNBC
Sentiment: Neutral
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
Read More
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Read More
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Published: June 13, 2025 by: Investopedia
Sentiment: Positive
Merck (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.
Read More
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
Published: June 12, 2025 by: Reuters
Sentiment: Neutral
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's Gardasil vaccine, court records show.
Read More
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Read More
Drug pricing reform talks with US government lack clarity, industry executives say
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.
Read More
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.
Read More
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Read More
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Read More
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
Read More
Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee
Published: June 10, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Angelica Peebles reports on news regarding vaccines.
Read More
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
Published: June 09, 2025 by: CNBC
Sentiment: Positive
The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter.
Read More
U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Published: June 09, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves Merck's ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season.
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Published: June 09, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
Is Merck Stock About To Crash?
Published: June 03, 2025 by: Forbes
Sentiment: Negative
Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average revenue growth compared to J&J's modest 4%, and Merck's operating cash flow margins are a healthier 33% versus J&J's 28%.
Read More
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
Read More
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.
Read More
Merck Stock's Ticking Keytruda Time Bomb
Published: June 02, 2025 by: Forbes
Sentiment: Negative
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000